353 related articles for article (PubMed ID: 17655371)
1. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Stocker SL; Williams KM; McLachlan AJ; Graham GG; Day RO
Clin Pharmacokinet; 2008; 47(2):111-8. PubMed ID: 18193917
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Turnheim K; Krivanek P; Oberbauer R
Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
[TBL] [Abstract][Full Text] [Related]
4. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
[TBL] [Abstract][Full Text] [Related]
5. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of oxypurinol in people with gout.
Stocker SL; McLachlan AJ; Savic RM; Kirkpatrick CM; Graham GG; Williams KM; Day RO
Br J Clin Pharmacol; 2012 Sep; 74(3):477-89. PubMed ID: 22300439
[TBL] [Abstract][Full Text] [Related]
11. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
12. An audit of a therapeutic drug monitoring service for allopurinol therapy.
Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
[TBL] [Abstract][Full Text] [Related]
13. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
[TBL] [Abstract][Full Text] [Related]
14. Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy.
Chung Y; Stocker SL; Graham GG; Day RO
Am J Med Sci; 2008 Mar; 335(3):219-26. PubMed ID: 18344696
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse.
Mills PC; Dunnett M; Smith NC
J Vet Pharmacol Ther; 1995 Dec; 18(6):451-6. PubMed ID: 8789699
[TBL] [Abstract][Full Text] [Related]
16. The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout.
Wilson LC; Ward J; Wright DFB; Green SC; Stocker SL; Putt TL; Schollum JBW; Walker RJ
Nephrology (Carlton); 2024 Apr; ():. PubMed ID: 38626950
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
Day RO; Miners JO; Birkett DJ; Whitehead A; Naidoo D; Hayes J; Savdie E
Br J Clin Pharmacol; 1988 Oct; 26(4):423-8. PubMed ID: 3190992
[TBL] [Abstract][Full Text] [Related]
18. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
Wright DF; Doogue MP; Barclay ML; Chapman PT; Cross NB; Irvine JH; Stamp LK
Eur J Clin Pharmacol; 2017 Jan; 73(1):71-78. PubMed ID: 27683090
[TBL] [Abstract][Full Text] [Related]
19. Individualising the dose of allopurinol in patients with gout.
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.
Ng DY; Stocker SL; Graham GG; Williams KM; Day RO
Eur J Clin Pharmacol; 2011 Jul; 67(7):709-13. PubMed ID: 21181139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
